Precision biosciences announces grant of inducement awards under nasdaq listing rule 5635(c)(4)

Durham, n.c.--(business wire)--precision biosciences, inc. (nasdaq: dtil), a clinical stage gene editing company utilizing its novel proprietary arcus® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on april 22, 2025, the compensation committee of precision's board of directors approved the grant of inducement awards to new employees under the precision biosciences, inc. 2021 employment inducement incentive award plan (“inducement awa.
NDAQ Ratings Summary
NDAQ Quant Ranking